PDCD1 and melanoma: Patients with asymptomatic brain metastases, BRAFV600-mutant melanoma or elevated serum lactate dehydrogenase (LDH) derive an incremental benefit from combination immunotherapy when compared to single agent anti-PD-1 [5,6], however routine upfront combination immunotherapy for stage IV melanoma patients is not cost-effective [7].